Conflicts of Interest disclosure statement M.A. Shah reports receiving commercial support from Gilead Sciences, Merck, Boston Biomedical, Oncolys BioPharma, Bristol-Myers Squibb and is a consultant /advisory board member for Astellas Pharma and Lilly Japan. The other authors declare no potential conflicts of interest.